可溶性CD163和甘露糖受体与慢性乙型肝炎活动和纤维化相关，

StephenW

J Gastroenterol Hepatol. 2017 Jun 15. doi: 10.1111/jgh.13849. [Epub ahead of print]
Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment.Laursen TL1, Wong GL2, Kazankov K1, Sandahl T1, Møller HJ3, Hamilton-Dutoit S4, George J5, Chan HL2, Grønbaek H1.
Author information
1Department of Hepatology & Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.2Department of Medicine and Therapeutics and Institute of Digestive Disease, the Chinese University of Hong Kong, Hong Kong, SAR, China.3Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.4Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark.5Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Australia.

AbstractBACKGROUND AND AIM: Liver macrophages are activated in chronic hepatitis B virus (CHB) infection and play a pivotal role in hepatic inflammation and fibrosis. However, their role during anti-viral treatment is unclear. The soluble (s) macrophage activation markers, sCD163 and mannose receptor (sMR), are released during liver damage and their serum levels reflect liver disease severity and portal hypertension. We aimed to investigate associations between sCD163 and sMR and histopathological activity and fibrosis, and changes in sCD163, sMR and hepatic CD163-expression following anti-viral treatment in CHB patients.
METHODS: We assessed Ishak histological necroinflammatory activity and fibrosis scores in liver biopsies from 254 CHB patients, and serially in 71 patients before and after nucleoside-analogue treatment. Liver CD163-expression was semi-quantitatively determined by immunohistochemistry and serum sCD163 and sMR measured by ELISA.
RESULTS: Before treatment, the mean levels of sCD163 and sMR were 3.57 (SD 1.72) mg L-1 and 0.35 (0.12) mg L-1 . sCD163 and sMR increased with histological inflammatory activity (sCD163: r=0.46, p<0.00001; sMR: r=0.48, p<0.00001) and correlated positively with fibrosis (sCD163: OR 1.16, 95%CI:1.03-1.31; sMR: OR 1.34, 95%CI:1.13-1.59); both were markers of fibrosis independent of other biochemical parameters and risk factors. Anti-viral treatment significantly reduced sCD163 (3.76 (1.46) vs. 2.31 (0.95), p<0.00001), sMR (0.37 (0.1) vs. 0.29 (0.07), p<0.00001) and hepatic CD163-expression (p=0.0002).
CONCLUSIONS: The macrophage activation markers sCD163 and sMR were associated with activity and fibrosis in liver biopsies from CHB patients. Both serum markers decreased with anti-viral treatment, along with decreased hepatic CD163 expression.


This article is protected by copyright. All rights reserved.



KEYWORDS: Anti-viral treatment; Hepatitis B; fibrosis; macrophages; soluble CD163; soluble mannose receptor

PMID:28618015DOI:10.1111/jgh.13849

• 
  


• 
  

StephenW

G胃肠肝炎2017年6月15日。doi：10.1111 / jgh.13849。 [提前印刷]
可溶性CD163和甘露糖受体与慢性乙型肝炎活动和纤维化相关，并随治疗而下降。
Laursen TL1，Wong GL2，Kazankov K1，Sandahl T1，MøllerHJ3，Hamilton-Dutoit S4，George J5，Chan HL2，GrønbaekH1。
作者信息

1
    丹麦奥胡斯奥胡斯大学医院肝脏与胃肠病学系。
2
    香港中文大学医学与治疗学院消化病研究所，香港特别行政区，中国。
3
    丹麦奥胡斯奥胡斯大学医院临床生物化学系。
4
    丹麦奥胡斯奥胡斯大学医院病理研究所。
五
    Storr肝脏中心，Westmead医学研究所，Westmead医院和澳大利亚悉尼大学。

抽象
背景与目的：

肝巨噬细胞在慢性乙型肝炎病毒（CHB）感染中被激活，并在肝脏炎症和纤维化中起关键作用。然而，它们在抗病毒治疗中的作用尚不清楚。可溶性巨噬细胞活化标志物sCD163和甘露糖受体（sMR）在肝损伤期间释放，其血清水平反映肝脏疾病严重程度和门静脉高压。我们旨在调查CHB患者抗病毒治疗后sCD163和sMR与组织病理学活性和纤维化之间的联系以及sCD163，sMR和肝脏CD163表达的变化。
方法：

我们评估了来自254例CHB患者肝活组织检查中Ishak组织学坏死性炎症活动和纤维化评分，并且在核苷类似物治疗前后均为71例。通过免疫组化法半定量测定肝脏CD163的表达，并通过ELISA测定血清sCD163和sMR。
结果：

治疗前，sCD163和sMR的平均水平分别为3.57（SD 1.72）mg L-1和0.35（0.12）mg L-1。 sCD163和sMR随组织学炎症活动而增加（sCD163：r = 0.46，p <0.00001; sMR：r = 0.48，p <0.00001），与纤维化呈正相关（sCD163：OR 1.16,95％CI：1.03-1.31; sMR：或1.34,95％CI：1.13-1.59）;两者都是纤维化的标志物，与其他生物化学参数和危险因素无关。抗病毒治疗显着降低sCD163（3.76（1.46）vs 2.31（0.95），p <0.00001），sMR（0.37（0.1）vs.0.29（0.07），p <0.00001）和肝CD163表达（p = 0.0002 ）。
结论：

巨噬细胞活化标志物sCD163和sMR与来自CHB患者的肝活组织检查中的活性和纤维化相关。两种血清标志物均随着抗病毒治疗而降低，同时肝脏CD163表达下降。

本文受版权保护。版权所有。
关键词：

抗病毒治疗;乙型肝炎纤维化;巨噬细胞;可溶性CD163;可溶性甘露糖受体

结论：
    28618015
DOI：
    10.1111 / jgh.13849